Tirzepatide: A dual GLP-1 and GIP receptor agonist that works across two metabolic pathways to help regulate hunger, insulin response, and weight loss outcomes
Buy now, pay later (BNPL) is a payment option that allows a customer to pay for a purchase over time in instalments while merchants get paid in full upfront
Cash Pay Options Manufacturer Direct Programs: Novo Nordisk: $199/month for first two doses, then $349/month Eli Lilly LillyDirect: $299-$499/month depending on dose TrumpRx Platform (Launching Early 2026): Injectable GLP-1s: $350/month initially, dropping to $250 within 2 years Oral GLP-1s (pending FDA approval): $149/month for starting doses GoodRx/Discount Cards: Prices vary by pharmacy and location Typically $900-$1,200/month without manufacturer programs Check current prices at your local Hinsdale pharmacies Cost Comparison: What You'll Actually Pay Ozempic (semaglutide for diabetes): Insurance copay: $25-$100/month Medicare (2026): $50/month Cash (manufacturer direct): $199-$349/month List price: $969/month Wegovy (semaglutide for obesity): Insurance copay: Often not covered Medicare (2026): $50/month Cash (manufacturer direct): $199-$349/month List price: $1,349/month Mounjaro (tirzepatide for diabetes): Insurance copay: $25-$100/month Medicare (2026): $50/month List price: $1,069/month Zepbound (tirzepatide for obesity): Insurance copay: Often not covered Medicare (2026): $50/month Cash (manufacturer direct): $299-$499/month List price: $1,059/month At Well Endocrinology, we help patients navigate insurance coverage, prior authorizations, and manufacturer savings programs to minimize out-of-pocket costs
Summary The piperine found in black pepper enhances curcumin absorption, making it more readily available to be used by your body
sDPP4 directly promoted human smooth muscle cell (hVSMC) proliferation and inflammation via NF-B activation resulting in the upregulation of pro-inflammatory cytokines such as monocyte chemoattractant protein (MCP)-1, IL-6 and IL-8, through a novel mechanism mediated by the activation of the protease activated receptor (PAR)-2 (Wronkowitz et al., 2014)
